Although remarkable progress has been made in cancer treatment by blocking CTLA-4 or PD-1 pathway with mAbs, most patients do not respond to therapy because of T cell-mediated primitive or acquired immune resistance to anti-tumor drugs (8, 39, 40). Here, CTLA4 is linked to cancer.